Immediate Impact
36 standout
Citing Papers
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
2025 Standout
Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets
2025 Standout
Works of Misbahuddin M. Rafeeq being referenced
Role and implications of the CXCL12/CXCR4/CXCR7 axis in atherosclerosis: still a debate
2021
Cystic fibrosis: current therapeutic targets and future approaches
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Misbahuddin M. Rafeeq | 156 | 55 | 38 | 115 | 45 | 447 | |
| Hussam Murad | 96 | 36 | 14 | 122 | 45 | 483 | |
| Hailiang Huang | 173 | 27 | 24 | 34 | 39 | 424 | |
| Jessica Friedman | 217 | 17 | 40 | 79 | 28 | 428 | |
| Mengrong Li | 231 | 79 | 9 | 43 | 36 | 471 | |
| Rafael Baltiérrez‐Hoyos | 175 | 23 | 12 | 86 | 44 | 454 | |
| Lujin Li | 86 | 43 | 16 | 38 | 64 | 498 | |
| Jun Zhao | 205 | 16 | 18 | 44 | 55 | 511 | |
| Zhongde Zhang | 128 | 17 | 22 | 52 | 34 | 435 | |
| Abdulrahman Alwhaibi | 187 | 14 | 19 | 56 | 47 | 438 | |
| Qian Yan | 199 | 13 | 19 | 54 | 45 | 393 |
All Works
Login with ORCID to disown or claim papers
Loading papers...